TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9679876

Group type: EXPERIMENTAL
Intervention: Filiform dilation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Internal urethrotomy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Second dilation or urethrotomy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Third dilation or urethrotomy
Number of subjects: 210
Study: 7916274

Group type: EXPERIMENTAL
Intervention: Exercise stress echocardiography
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (beta-blocker therapy)
Number of subjects: 136
Study: 2688346

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg IV every 6 hours for 8 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No ranitidine (control group)
Number of subjects: 25
Study: 472340

Group type: EXPERIMENTAL
Intervention: 2.5 mg 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3 mg 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vaginal administration of 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonpregnant patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 16
Study: 30878222

Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 μg/kg) and albendazole (400 mg) plus five further doses of ivermectin alone at 3-week intervals over 18 weeks
Number of subjects: 2712

Group type: COMPARATOR
Intervention: Control group received single oral doses of ivermectin (150-200 μg/kg) and albendazole (400 mg) without further doses of ivermectin
Number of subjects: 2712

Group type: EXPERIMENTAL
Intervention: Ivermectin (intervention group)
Number of subjects: 2712

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2712
Study: 28057693

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2004
Study: 26336866

Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 44

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 44
Study: 23338110

Group type: EXPERIMENTAL
Intervention: bupivacaine 8.0 mg + clonidine 75 µg + morphine 100 µg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: bupivacaine 10 mg + clonidine 75 µg + morphine 100 µg
Number of subjects: 66
Study: 20625342

Group type: EXPERIMENTAL
Intervention: Hypothermia therapy (32.5°C) for 24 hours, started within 8 hours of injury and rewarming at a rate of 0.5°C every 2 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normothermia (37.0°C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Serum GFAP measured on day 1 post-TBI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Serum GFAP cutoff level of 0.6 ng/mL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid GFAP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Serum GFAP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for pediatric intensive care unit day 1 serum GFAP
Number of subjects: 27
Study: 19759431

Group type: EXPERIMENTAL
Intervention: Background music prior to attention test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Background music during attention test
Number of subjects: 32

Group type: COMPARATOR
Intervention: No background music
Number of subjects: 32
Study: 18025525

Group type: EXPERIMENTAL
Intervention: 200 mg bid voriconazole
Number of subjects: 34

Group type: COMPARATOR
Intervention: 400 mg qd efavirenz
Number of subjects: 34
Study: 14987322

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg b.d. plus dietary treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 36
Study: 11601952

Group type: EXPERIMENTAL
Intervention: Quality indicators for the management of heart failure
Number of subjects: 0
Study: 9270067

Group type: EXPERIMENTAL
Intervention: Acentrally active drug that enhances AMPA receptor‐mediated currents
Number of subjects: 0
Study: 8417487

Group type: EXPERIMENTAL
Intervention: Surgical techniques (bilateral vagotomy plus Heineke‐Mikulicz pyloroplasty, bilateral truncal vagotomy plus anterior pylorectomy, proximal gastric vagotomy, antrectomy and Billroth I reconstruction, and antrectomy and Billroth II reconstruction)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation between 99mTc‐HIDA and bile acids
Number of subjects: 50
Study: 3535551

Group type: EXPERIMENTAL
Intervention: Nonwoven, disposable gown and drape fabrics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reusable cotton poplin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (nonwoven and reusable fabrics)
Number of subjects: 0
Study: 11733393

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30742718

Group type: EXPERIMENTAL
Intervention: Maternal asthma
Number of subjects: 1579263

Group type: EXPERIMENTAL
Intervention: Paternal asthma
Number of subjects: 1579263

Group type: EXPERIMENTAL
Intervention: Maternal asthma among paternal half-siblings
Number of subjects: 1579263

Group type: EXPERIMENTAL
Intervention: Maternal asthma among full-cousins
Number of subjects: 1579263

Group type: EXPERIMENTAL
Intervention: Maternal asthma among half-cousins
Number of subjects: 1579263

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to asthma medications among mothers with asthma
Number of subjects: 1579263
Study: 28629282

Group type: EXPERIMENTAL
Intervention: Religious trauma‐writing condition
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional trauma‐writing condition
Number of subjects: 105
Study: 24747626

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) patches applied once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study: 23285271

Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated Internet Training Program (ITP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ISG and ITP (ITP+ISG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control website with delayed access to e-couch
Number of subjects: 0
Study: 20584114

Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg diluted in 10 mL of distilled water daily, N=37)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (10 mL of saline water, N=37)
Number of subjects: 86
Study: 17356786

Group type: EXPERIMENTAL
Intervention: Adjustable medication dosing
Number of subjects: 228

Group type: COMPARATOR
Intervention: Fixed medication dosing
Number of subjects: 228
Study: 15365685

Group type: EXPERIMENTAL
Intervention: Intravenous citalopram (10 mg, 20 mg, 40 mg, 0.33 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 12166339

Group type: EXPERIMENTAL
Intervention: Incadronate (10 mg intravenous infusion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Elcatonin (40 IU intramuscular injections twice daily for 7 days)
Number of subjects: 26
Study: 10439722

Group type: EXPERIMENTAL
Intervention: Punitive damage caps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifurcation of compensatory and punitive damage decisions
Number of subjects: 0
Study: 7791151

Group type: EXPERIMENTAL
Intervention: Salsalate 3.0 g/day (titrated to 3.55 g/day)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Diclofenac 75 mg/day (titrated to 112 mg/day)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 301

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 301
Study: 1983322

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine b.d.
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine nocte
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 583489

Group type: EXPERIMENTAL
Intervention: Preparation A (Digacin)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preparation B
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preparation C
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preparation D
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 19
Study: 30423462

Group type: EXPERIMENTAL
Intervention: Inflammatory stress (Salmonella typhi vaccine)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28467857

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR; 2.4 ± 0.2 h of sleep)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON; 7.1 ± 0.3 h of sleep)
Number of subjects: 7
Study: 26506050

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 24352094

Group type: EXPERIMENTAL
Intervention: 7% carbohydrate (CHO) solution (700 mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0% CHO) (700 mL)
Number of subjects: 22
Study: 20629764

Group type: EXPERIMENTAL
Intervention: DECISION+ intervention (experimental group)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control group (delayed DECISION+)
Number of subjects: 492
Study: 19835121

Group type: EXPERIMENTAL
Intervention: Suspended moxibustion on temperature-sensitive acupoints plus herbal enema
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moxibustion at Guanyuan (CV 4), Zhongji (CV 3), Shenshu (BL 23) combined with herbal enema
Number of subjects: 60
Study: 18246965

Group type: EXPERIMENTAL
Intervention: 9% hydrogen peroxide gel (Colgate Visible White)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 20% carbamide peroxide gel (Opalescence)
Number of subjects: 46
Study: 15358464

Group type: COMPARATOR
Intervention: Human Tubal Fluid (HTF)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Preimplantation Stage One (P1)
Number of subjects: 109
Study: 11410799

Group type: EXPERIMENTAL
Intervention: 2 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 4 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 2 microg/kg G‐CSF (lenograstim) when grade 2 leukopenia or neutropenia appeared (Group 3)
Number of subjects: 68
Study: 9534714

Group type: EXPERIMENTAL
Intervention: Fractionated radiotherapy protocols
Number of subjects: 0

Group type: COMPARATOR
Intervention: British Institute of Radiology's trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recent studies
Number of subjects: 0
Study: 8328239

Group type: EXPERIMENTAL
Intervention: Aylesbury spatula
Number of subjects: 14172

Group type: EXPERIMENTAL
Intervention: Rolon spatula
Number of subjects: 14172

Group type: EXPERIMENTAL
Intervention: Cervex device
Number of subjects: 14172

Group type: EXPERIMENTAL
Intervention: Aylesbury spatula with Cytobrush
Number of subjects: 14172

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14172
Study: 3113331

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg) given twice a day for 2 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 30881050

Group type: EXPERIMENTAL
Intervention: Iodixanol nasal solution
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 28408039

Group type: EXPERIMENTAL
Intervention: Binocular visual function tests (Esterman VF score, binocular VA)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Binocular VA
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: VAQ
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Better-eye, average-eye, and binocular summation of VA
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Binocular VF testing
Number of subjects: 607
Study: 25647746

Group type: EXPERIMENTAL
Intervention: Different position ventilation group (n=34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Supine position ventilation group (n=33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 22766389

Group type: EXPERIMENTAL
Intervention: Glucose drink (25 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink (30 mg saccharine)
Number of subjects: 20
Study: 21486921

Group type: EXPERIMENTAL
Intervention: Baseline vitamin E concentrations
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Time‐varying vitamin E concentrations
Number of subjects: 148
Study: 18645322

Group type: EXPERIMENTAL
Intervention: FES + exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: exercise-only
Number of subjects: 26
Study: 17031805

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo stretching (PS)
Number of subjects: 20
Study: 12721240

Group type: EXPERIMENTAL
Intervention: Glutamine (4 g orally, twice a day for 2 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (4 g orally, twice a day for 2 weeks)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: COMPARATOR
Intervention: Glutamine and Placebo
Number of subjects: 129
Study: 10570413

Group type: EXPERIMENTAL
Intervention: Revised 1997 TNM staging system
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage I
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage IIA
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage IIB
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage IVA
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Stage IVB
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Cranial nerve involvement
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Orbit involvement
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Intracranial involvement
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Paraoropharyngeal involvement
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Lateral spread to the medial infratemporal fossa
Number of subjects: 677
Study: 8649495

Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous bone marrow transplantation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 200
Study: 1951216

Group type: EXPERIMENTAL
Intervention: Microcomputer-based tutorial (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific reading material (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 0
Study: 6299503

Group type: EXPERIMENTAL
Intervention: Combined pelvic x-ray therapy plus a perineal proton beam boost (500 to 700 cGy dose to prostatic tumor)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional pelvic megavoltage x-ray therapy
Number of subjects: 180
Study: 31154818

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28678849

Group type: EXPERIMENTAL
Intervention: CHAMPION intervention package (community health promotion and provision of health services)
Number of subjects: 29669

Group type: EXPERIMENTAL
Intervention: CHAMPION intervention package
Number of subjects: 29669
Study: 26860023

Group type: EXPERIMENTAL
Intervention: 20.25 mg of hyperbaric ropivacaine in 5% dextrose (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 20.25 mg of plain ropivacaine (group A)
Number of subjects: 80
Study: 22840340

Group type: EXPERIMENTAL
Intervention: VCS clips
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prolene sutures
Number of subjects: 24
Study: 21163558

Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (sesame oil + glibenclamide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60
Study: 19570039

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 0
Study: 17115133

Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with 4Vent helmet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with PN500 helmet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with CaStar helmet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CPAP with safety valve open
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CPAP with safety valve locked
Number of subjects: 5
Study: 15036782

Group type: EXPERIMENTAL
Intervention: Mutual exposure among freshman college roommates over seven months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best friends in third grade classrooms
Number of subjects: 0
Study: 12170362

Group type: EXPERIMENTAL
Intervention: High-dose methyl prednisolone (30 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose methyl prednisolone (2 mg/kg)
Number of subjects: 30
Study: 10660865

Group type: EXPERIMENTAL
Intervention: Inosine supplementation (10,000 mg.d‐1)
Number of subjects: 7
Study: 7749832

Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR < 1.7
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR 1.7 to 2.5
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR > 2.5
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warfarin treatment (general)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warfarin treatment in patients with congenital antithrombin III or protein C deficiency
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warfarin discontinuation in one patient
Number of subjects: 74
Study: 2301259

Group type: EXPERIMENTAL
Intervention: Dynamic treadmill exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isodynamic exercise (treadmill walking 1.5 to 2.0 mph carrying 15 to 25 kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline submaximal treadmill exercise test
Number of subjects: 11
Study: 7461761

Group type: EXPERIMENTAL
Intervention: PPD-G
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPD-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPD-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPD-F
Number of subjects: 0
Study: 6136059

Group type: EXPERIMENTAL
Intervention: Depot neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 41
Study: 29401082

Group type: EXPERIMENTAL
Intervention: Delayed initiation of oral feeding (1 week later)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (started oral feeding when physiologically stable)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study: 26360934

Group type: EXPERIMENTAL
Intervention: In-person group intervention composed of six 90-min sessions over 4 weeks with follow-up phone calls
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: In-person group intervention
Number of subjects: 131
Study: 24788974

Group type: EXPERIMENTAL
Intervention: Functionally independent group
Number of subjects: 19748

Group type: EXPERIMENTAL
Intervention: Functionally partially dependent group
Number of subjects: 19748

Group type: COMPARATOR
Intervention: Functionally partially dependent vs. functionally independent
Number of subjects: 19748
Study: 22564241

Group type: EXPERIMENTAL
Intervention: WATERCISE group (aqua-training programme once a week for 1 h over 12 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no aqua-training)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: WATERCISE group
Number of subjects: 28
Study: 20029984

Group type: EXPERIMENTAL
Intervention: Ondansetron (group A)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (group B)
Number of subjects: 562
Study: 18416725

Group type: EXPERIMENTAL
Intervention: Immediate loading (temporary restoration on the day of surgery)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Early loading (temporary restoration 28-34 days after surgery)
Number of subjects: 266
Study: 15671185

Group type: EXPERIMENTAL
Intervention: Enhanced care (active treatment with practice nurses for 24 months)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 211
Study: 12791219

Group type: EXPERIMENTAL
Intervention: Analgesics administered before surgical evaluation
Number of subjects: 0
Study: 10496260

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) carbidopa/levodopa
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) carbidopa/levodopa
Number of subjects: 618
Study: 7793557

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml applied locally to the knee at the end of the procedure (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piroxicam 20 mg intramuscularly (n = 30)
Number of subjects: 60
Study: 1771701

Group type: EXPERIMENTAL
Intervention: 20 mg trospium chloride twice daily for 3 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7044532

Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy with radiation therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy with radiation therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combined arms with chemotherapy and/or immunotherapy
Number of subjects: 107
Study: 31918243

Group type: EXPERIMENTAL
Intervention: Motor-phonetic treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined phonetic-phonological treatment
Number of subjects: 8